ATE424409T1 - Chimere human papilloma virus 16 l1 proteine, welche ein l2 peptid enthalten, damit hergestellte virus-ähnliche partikel und methode zur herstellung der partikel - Google Patents

Chimere human papilloma virus 16 l1 proteine, welche ein l2 peptid enthalten, damit hergestellte virus-ähnliche partikel und methode zur herstellung der partikel

Info

Publication number
ATE424409T1
ATE424409T1 AT03727750T AT03727750T ATE424409T1 AT E424409 T1 ATE424409 T1 AT E424409T1 AT 03727750 T AT03727750 T AT 03727750T AT 03727750 T AT03727750 T AT 03727750T AT E424409 T1 ATE424409 T1 AT E424409T1
Authority
AT
Austria
Prior art keywords
virus
particles
peptide
producing
dna sequence
Prior art date
Application number
AT03727750T
Other languages
English (en)
Inventor
Arvind Varsani
Edward Rybicki
Original Assignee
Univ Cape Town
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29550639&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE424409(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Cape Town filed Critical Univ Cape Town
Application granted granted Critical
Publication of ATE424409T1 publication Critical patent/ATE424409T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03727750T 2002-05-17 2003-05-19 Chimere human papilloma virus 16 l1 proteine, welche ein l2 peptid enthalten, damit hergestellte virus-ähnliche partikel und methode zur herstellung der partikel ATE424409T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ZA200203957 2002-05-17

Publications (1)

Publication Number Publication Date
ATE424409T1 true ATE424409T1 (de) 2009-03-15

Family

ID=29550639

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03727750T ATE424409T1 (de) 2002-05-17 2003-05-19 Chimere human papilloma virus 16 l1 proteine, welche ein l2 peptid enthalten, damit hergestellte virus-ähnliche partikel und methode zur herstellung der partikel

Country Status (13)

Country Link
US (2) US7407807B2 (de)
EP (1) EP1506222B2 (de)
JP (2) JP4614765B2 (de)
AT (1) ATE424409T1 (de)
AU (1) AU2003232951B2 (de)
CA (1) CA2486450C (de)
CY (1) CY1109257T1 (de)
DE (1) DE60326449D1 (de)
DK (1) DK1506222T3 (de)
ES (1) ES2323634T5 (de)
PT (1) PT1506222E (de)
SI (1) SI1506222T1 (de)
WO (1) WO2003097673A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228715D0 (en) * 2002-12-09 2003-01-15 Glaxosmithkline Biolog Sa Vaccine
CN101166827B (zh) 2005-04-29 2013-09-04 开普敦大学 在植物中表达蛋白质
ES2310062B1 (es) 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
CN1328287C (zh) * 2005-12-29 2007-07-25 西安交通大学 Hpv16 l1蛋白模拟肽及其用于制备hpv16诊断试剂和疫苗的用途
US20100260792A1 (en) * 2007-10-22 2010-10-14 University Of Rochester Respiratory syncytial virus vaccine based on chimeric papillomavirus virus-like particles or capsomeres
CA2768172A1 (en) * 2009-06-25 2010-12-29 Glaxosmithkline Biologicals S.A. Novel compositions
WO2011017162A2 (en) * 2009-08-03 2011-02-10 The Johns Hopkins University Methods for enhancing antigen-specific immune responses
CA2799205A1 (en) 2010-05-25 2011-12-01 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically-truncated probes
CN103890177B (zh) * 2011-12-01 2016-03-09 开普敦大学 Hpv嵌合颗粒
WO2015009853A1 (en) * 2013-07-16 2015-01-22 University Of Louisville Research Foundation, Inc. Compositions for mucusal delivery, useful for treating papillomavirus infections
WO2015192018A1 (en) 2014-06-12 2015-12-17 Iowa Approach Inc. Method and apparatus for rapid and selective tissue ablation with cooling
JP7017811B2 (ja) * 2020-02-13 2022-02-09 国立研究開発法人農業・食品産業技術総合研究機構 ウイルス様粒子及びその使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
EP1728800A1 (de) * 1994-10-07 2006-12-06 Loyola University Of Chicago Papillomavirusähnliche Partikel, Fusionsproteine sowie Verfahren zu deren Herstellung
GB9621091D0 (en) * 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
US6228368B1 (en) † 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
DE19812941A1 (de) † 1998-03-24 1999-10-07 Medigene Ag Arzneimittel zur Vermeidung oder Behandlung von Papillomavirusspezifischem Tumor
US6926897B1 (en) † 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
DE69933875T2 (de) * 1998-08-14 2007-05-31 Merck & Co., Inc. Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
GB9921146D0 (en) † 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
EP2416798B1 (de) † 2009-04-10 2017-09-20 The Johns Hopkins University Papillomavirus-like partikel (vlp) als breitbandimpfstoffe gegen humanes papillomavirus (hpv)

Also Published As

Publication number Publication date
US20060035319A1 (en) 2006-02-16
US8163557B2 (en) 2012-04-24
EP1506222B2 (de) 2012-05-23
CA2486450A1 (en) 2003-11-27
AU2003232951A1 (en) 2003-12-02
JP4614765B2 (ja) 2011-01-19
EP1506222B1 (de) 2009-03-04
US7407807B2 (en) 2008-08-05
PT1506222E (pt) 2009-06-12
WO2003097673A2 (en) 2003-11-27
AU2003232951B2 (en) 2009-07-23
EP1506222A2 (de) 2005-02-16
DE60326449D1 (de) 2009-04-16
ES2323634T5 (es) 2012-09-04
WO2003097673B1 (en) 2004-04-22
WO2003097673A3 (en) 2004-03-18
CY1109257T1 (el) 2014-07-02
CA2486450C (en) 2013-11-19
SI1506222T1 (sl) 2009-10-31
US20090047302A1 (en) 2009-02-19
ES2323634T3 (es) 2009-07-22
DK1506222T3 (da) 2009-07-06
JP2010263899A (ja) 2010-11-25
JP2006507797A (ja) 2006-03-09

Similar Documents

Publication Publication Date Title
CY1109257T1 (el) Χιμαιρικες πρωτεϊνες l1 του ιου 16 ανθρωπινων θηλωματων που περιλαμβανουν l2 πεπτιδιο, ομοιαζοντα με ιο σωματιδια που παρασκευαζονται απο αυτες και μεθοδος παρασκευης των σωματιδιων
DE122011100018I1 (de) Herstellung von menschlichem Papilloma-Virus-Capsid-Protein und virusahnlichen Teilchen.
JP2015037430A (ja) パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
NL300313I1 (nl) Vaccin tegen humaan papillomavirus
ATE386800T1 (de) Immunogene chimäre umfassend nucleinsäuresequenzen, die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten
EP1018557A3 (de) Infektiöser cDNA Klon des das Reproduktions- und Atemwegs-Syndrom verursachenden Nord-Amerikanischen Schweinevirus und dessen Verwendung
CA2302545A1 (en) In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps)
EP1605052A3 (de) Methode für die Produktion von multivalenten Influenza Hämagglutinin Vakzinen
WO2003077942A3 (en) Virus-like particles of human papillomavirus
DE69834671D1 (de) Immunantwort gegen HPV Antigene hervorgerufen von Zusammensetzungen die ein HPV Antigen und ein Stressprotein enthalten oder einem Expressionsvektor fähig zur Expression dieser Proteine
WO2003078455A3 (en) Virus like particle from papillomavirus and their use in vaccine
IL175021A0 (en) Chromatin insulator, its preparation and use in protein expression
MXPA02012593A (es) Particulas de tipo virus del virus de la diarrea viral bovina.
JP2006507797A5 (de)
ATE494377T1 (de) Vakzine gegen ipnv die aus hefezellen isoliert werden
WO2002038769A3 (de) Für expression in eukaryonten optimierte hpv 16-l1 und hpv 16-l2 kodierende dna-sequenzen
IL104003A0 (en) Recombinant vaccines and method of producing same

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1506222

Country of ref document: EP